CA2120500A1 - Prevention du rejet d'allogreffes avec des anticorps contre des molecules d'adhesion - Google Patents

Prevention du rejet d'allogreffes avec des anticorps contre des molecules d'adhesion

Info

Publication number
CA2120500A1
CA2120500A1 CA002120500A CA2120500A CA2120500A1 CA 2120500 A1 CA2120500 A1 CA 2120500A1 CA 002120500 A CA002120500 A CA 002120500A CA 2120500 A CA2120500 A CA 2120500A CA 2120500 A1 CA2120500 A1 CA 2120500A1
Authority
CA
Canada
Prior art keywords
receptor
inhibitor
antibodies
ligand
lfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002120500A
Other languages
English (en)
Inventor
Mitsuaki Isobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2120500A1 publication Critical patent/CA2120500A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002120500A 1991-10-01 1992-09-29 Prevention du rejet d'allogreffes avec des anticorps contre des molecules d'adhesion Abandoned CA2120500A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01
US768,044 1991-10-01

Publications (1)

Publication Number Publication Date
CA2120500A1 true CA2120500A1 (fr) 1993-04-15

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002120500A Abandoned CA2120500A1 (fr) 1991-10-01 1992-09-29 Prevention du rejet d'allogreffes avec des anticorps contre des molecules d'adhesion

Country Status (8)

Country Link
EP (1) EP0610298A1 (fr)
JP (1) JPH07502727A (fr)
AU (1) AU667487B2 (fr)
CA (1) CA2120500A1 (fr)
HU (1) HUT69725A (fr)
MX (1) MX9205637A (fr)
WO (1) WO1993006864A1 (fr)
ZA (1) ZA927503B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323171B2 (en) 1991-10-07 2008-01-29 Astellas Us Llc Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
US7662921B2 (en) 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015764A1 (fr) * 1992-02-12 1993-08-19 Biogen, Inc. Traitement de l'inflammation intestinale
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2005254980A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2008140484A2 (fr) 2006-11-09 2008-11-20 Xdx, Inc. Procédés pour diagnostiquer et surveiller l'état d'un lupus érythémateux systémique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
EP0365837B1 (fr) * 1988-09-28 1995-08-02 Dana Farber Cancer Institute Molécules d'adhésion intercellulaire et leurs ligands de liaison
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
EP0387701B1 (fr) * 1989-03-09 1992-08-12 Boehringer Ingelheim Pharmaceuticals Inc. Utilisation des molécules d'adhésion intercellulaire et leurs ligands de liaison dans le traitement de l'asthme
WO1990013316A1 (fr) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination de cellules infectees par l'hiv-1
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323171B2 (en) 1991-10-07 2008-01-29 Astellas Us Llc Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US7662921B2 (en) 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders

Also Published As

Publication number Publication date
MX9205637A (es) 1993-05-01
JPH07502727A (ja) 1995-03-23
AU2782992A (en) 1993-05-03
EP0610298A1 (fr) 1994-08-17
HUT69725A (en) 1995-09-28
AU667487B2 (en) 1996-03-28
WO1993006864A1 (fr) 1993-04-15
ZA927503B (en) 1993-05-03
HU9400930D0 (en) 1994-06-28

Similar Documents

Publication Publication Date Title
Bahmani et al. Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival
Scheynius et al. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1.
Platt et al. Immune cell populations in cutaneous delayed-type hypersensitivity.
EP0656789B1 (fr) Procede pour traiter une affection ayant pour origine l'antigene 1 associe a la fonction lymphocytaire
DE69916807T2 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
US6406696B1 (en) Methods of stimulating the immune system with anti-CD3 antibodies
US7638121B2 (en) Methods for human allografting
Pavlath et al. Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers.
Quesenberry et al. Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice
WO1990013316A1 (fr) Dissemination de cellules infectees par l'hiv-1
Lambrigts et al. Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti‐αGal antibody in the baboon
CA2120500A1 (fr) Prevention du rejet d'allogreffes avec des anticorps contre des molecules d'adhesion
US20120269806A1 (en) Methods of inducing tolerance
CA3021645A1 (fr) Ciblage du systeme immunitaire inne pour induire une tolerance a long terme et pour resoudre l'accumulation de macrophages dans l'atherosclerose
CA2291338A1 (fr) Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
Guo et al. Long‐term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion
WO1995013093A1 (fr) Traitement d'un patient avant une transplantation
EP0972519A1 (fr) Inducteurs de tolerance immunitaire
Coito et al. Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients
Gudemez et al. Effect of anti-ICAM-1 antibodies on macromolecular leakage and leukocyte activation: a study of hindlimb allografts in the rat
Koulmanda et al. Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti‐T cell monoclonal antibody‐treated NOD mice
Halldórsdóttir Methods for tracking adoptively transferred T cells and enhancing efficacy of cellular therapies
Huang et al. Cell therapies and its derivatives as immunomodulators in vascularized composite allotransplantation

Legal Events

Date Code Title Description
FZDE Dead